How did ImmunityBio's revenue surge in Q4 2024?

ImmunityBio's revenue surged in Q4 2024 due to several key factors: 1. **Permanent J-Code Approval**: The issuance of a permanent J-code for ANKTIV A in January 2025 significantly boosted sales momentum. This regulatory approval facilitated wider reimbursement and accessibility of the therapy, leading to a 67% month-over-month increase in sales volume for ANKTIV A in February 2025 compared to January 2025. 2. **Increased Unit Sales Volume**: The company reported a substantial increase in unit sales volume for ANKTIVA A, with February 2025 sales demonstrating a 97% growth compared to December 2024. This significant uptick in sales volume directly contributed to the revenue surge. 3. **Strategic Developments**: ImmunityBio's strategic advancements, including FDA authorization for expanded access to recombinant BCG and the submission of marketing authorization applications in the EU and UK for ANKTIVA, have bolstered the company's market position and potential for future growth. These factors, among others, have collectively contributed to ImmunityBio's robust revenue growth in Q4 2024.